RIEB, Kobe University

Kanematsu Seminar (Jointly supported by: India Business Seminar)

Date&Time	Friday, May 25, 2012, 2:00pm-
Place	Room No.502, Academia Hall for Social Sciences 5th floor
Intended Audience	Faculty, Graduate Students, Undergraduates, and People with Equivalent Knowledge
Language	Japanese
Note	Copies of the paper will be available at Office of Promoting Research Collaboration.

2:00pm-2:10pm

An explanation from the moderator	Takahiro SATO（RIEB, Kobe University）

2:10pm-2:50pm

Speaker	Isao TAKAGAKI
Affiliation	Matsuda & Partners
Topic	How to resolve the disputes in India

2:50pm-3:30pm

Speaker	Yohei KOYAMA
Affiliation	Mori Hamada & Matsumoto
Topic	Legal Affairs in Doing Business in India

3:40pm-4:20pm

Speaker	Atsushi KAWAMOTO
Affiliation	Policy Research Institute, the Ministry of Finance
Topic	Macro economy and Financial Flows in India and Japan

4:20pm-5:00pm

Speaker	Atsuko KAMIIKE
Affiliation	National Museum of Ethnology
Topic	General Overview of the Indian Pharmaceutical Industry
Abstract	Recently, the business environment for the Japanese pharmaceutical industry has turned unfavourable. The factors such as pricing pressure due to constriction of the national health budget, patent expires of major block buster drugs, increasing R&D spending year by year, decline in R&D productivity, weaker product pipeline, fewer approvals and launches, and competition with generic drugs due to the promotion of the use of generic drugs by the Japanese government have put pressure on the Japanese pharmaceutical companies' bottom lines. The Japanese pharmaceutical industry seeks new growth opportunities. In this context, the Indian pharmaceutical industry started gaining attention in Japan. We would like to consider the attractiveness of the Indian pharmaceutical industry as an emerging pharmaceutical market and business alliance partner, and the business risks in India.